Lipoprotein apheresis (LA) has proven to be an effective, safe and life-saving therapy. Vascular access is needed to facilitate this treatment but has recognised complications. Despite consistency in treatment indication and duration there are no guidelines in place. The aim of this study is to characterise vascular access practice at the UK’s largest LA centre and forward suggestions for future approaches.
Methods:
A retrospective analysis of vascular access strategies was undertaken in all patients who received LA treatment in the low-density lipoprotein (LDL) Apheresis Unit at Harefield Hospital (Middlesex, UK) from November 2000 to March 2016.
Results:
Fifty-three former and current patients underwent 4260 LA treatments. Peripheral vein cannulation represented 79% of initial vascular access strategies with arteriovenous (AV) fistula use accounting for 15%. Last used method of vascular access was peripheral vein cannulation in 57% versus AV fistula in 32%. Total AV fistula failure rate was 37%.
Conclusions:
Peripheral vein cannulation remains the most common method to facilitate LA. Practice trends indicate a move towards AV fistula creation; the favoured approach receiving support from the expert body in this area. AV fistula failure rate is high and of great concern, therefore we suggest the implementation of upper limb ultrasound vascular mapping in all patients who meet treatment eligibility criteria. We encourage close ties between apheresis units and specialist surgical centres to facilitate patient counselling and monitoring. Further prospective data regarding fistula failure is needed in this expanding treatment field.
KraussRM. Heterogeneity of plasma low-density lipoproteins and atherosclerosis risk. Curr Opin Lipidol. 1994;5(5):339–349.
2.
StamlerJWentworthDNeatonJD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256(20):2823–2828.
3.
Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
4.
GrundySMCleemanJIMerzCNet al. Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. J Am Coll Cardiol. 2004;44(3):720–732.
5.
HopkinsPNTothPPBallantyneCMRaderDJ; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3)(Suppl):S9–S17.
6.
VellaAPinedaAAOBrienT. Low-density LA for the treatment of refractory hyperlipidemia. Mayo Clin Proc. 2001;76(10):1039–1046.
7.
ArchontakisSPottleAHakimNIlsleyCBarbirM. LDL-apheresis: indications and clinical experience in a tertiary cardiac centre. Int J Clin Pract. 2007;61(11):1834–1842.
8.
ThompsonGRLowenthalRMyantNB. Plasma exchange in the management of homozygous familial hypercholesterolaemia. Lancet. 1975;1(7918):1208–1211.
9.
ThompsonGR. The evidence-base for the efficacy of LA in combating cardiovascular disease. Atheroscler Suppl. 2013;14(1): 67–70.
10.
KellerC. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich experience. Atheroscler Suppl. 2009;10(5):21–26.
11.
MabuchiHKoizumiJShimizuMet al. Long-term efficacy of low-density LA on coronary heart disease in familial hypercholesterolemia. Am J Cardiol. 1998;82(12):1489–1495.
National Institute for Health and Care Excellence (2016). Familial hypercholesterolaemia: identification and management. NICE guideline (CG71). Available from: https://www.nice.org.uk/guidance/cg71/chapter/1-guidance. Accessed May 13, 2017.
19.
GordonBRKelseySFDauPCet al. Long-term effects of low-density LA using an automated dextran sulfate cellulose adsorption system. Am J Cardiol. 1998;81(4):407–411.
20.
BeigelRBeigelY. Homozygous familial hypercholesterolemia: long term clinical course and plasma exchange therapy for two individual patients and review of the literature. J Clin Apher. 2009;24(6):219–224.
21.
IrishADograGMoriTet al. Preventing AVF thrombosis: the rationale and design of the Omega-3 fatty acids (Fish Oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) study. BMC Nephrol. 2009;10(1):1.
22.
PetersonWJBarkerJAllonM. Disparities in fistula maturation persist despite preoperative vascular mapping. Clin J Am Soc Nephrol. 2008;3(2):437–441.
23.
HemodialysisA. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006. Am J Kidney Dis. 2006;48(Suppl 1):S2–S90.
24.
AllonMDaugirdasJDepnerTAGreeneTOrntDSchwabSJ. Effect of change in vascular access on patient mortality in hemodialysis patients. Am J Kidney Dis. 2006;47(3):469–477.
25.
WasseHKutnerNZhangRHuangY. Association of initial hemodialysis vascular access with patient-reported health status and quality of life. Clin J Am Soc Nephrol. 2007;2(4):708–714.
26.
SteenkampRRaoARoderickP. UK Renal Registry 17th Annual Report: Chapter 5 survival and cause of death in UK adult patients on renal replacement therapy in 2013: national and centre-specific analyses. Nephron. 2015;129(s1)(Suppl 1):99–129.
27.
De MarchiSFalletiEGiacomelloRet al. Risk factors for vascular disease and arteriovenous fistula dysfunction in hemodialysis patients. J Am Soc Nephrol. 1996;7(8):1169–1177.
28.
LappegårdKTHovlandA. Side effects in LDL apheresis: types, frequency and clinical relevance. Clin Lipidol. 2011;6(6):717–722.
29.
VishwanathRHemphillLC. Familial hypercholesterolemia and estimation of US patients eligible for low-density LA after maximally tolerated lipid-lowering therapy. J Clin Lipidol. 2014;8(1):18–28.
30.
ThompsonGR. HEART-UK LDL Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis. 2008;198(2):247–255.
31.
KhanTZPottleAPennellDJBarbirMS. The expanding role of lipoprotein apheresis in the treatment of raised lipoprotein(a) in ischaemic heart disease and refractory angina. Glob Cardiol Sci Pract. 2014; (1):3–12.
32.
RothEMMcKenneyJMHanotinCAssetGSteinEA. Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia. N Engl J Med. 2012;367(20):1891–1900.
33.
RobinsonJGNedergaardBSRogersWJet al. LAPLACE-2 Investigators. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. JAMA. 2014;311(18):1870–1882.
34.
StefanuttiCThompsonGR. LA in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr Atheroscler Rep. 2015;17(1):1–0.
35.
KalantariK. The choice of vascular access for therapeutic apheresis. J Clin Apher. 2012;27(3):153–159.
36.
HeiglFHettichRLotzNet al. Efficacy, safety, and tolerability of long-term LA in patients with LDL-or Lp (a) hyperlipoproteinemia: findings gathered from more than 36,000 treatments at one center in Germany. Atheroscler Suppl. 2015; 18:154–162.
